Development of an anticancer experimental drug with a novel structure generated by the Ronzoni Institute
Rome, May 13, 2013
Sigma-Tau Corporate R&D and its Swiss R&D subsidiary, sigma-tau Research Switzerland S.A., announce today that an international multicenter phase I study with the new proprietary anticancer agent SST0001 in Multiple Myeloma (MM) is fully up and running. Two Investigational sites (in Bergamo, Italy, and Tel Hashomer, Israel) are active and the enrolment of the first patient cohort has been completed. SST0001 is a new inhibitor of heparanase, an enzyme that plays an important role in cell growth and spread. Heparanase is a totally unexploited target and its inhibition may have great relevance in the therapy of cancer as well as of inflammatory diseases.